Lennox-Gastaut syndrome: A consensus approach to differential diagnosis

Permalink
https://escholarship.org/uc/item/32x6w7dt

Authors
Bourgeois, BFD
Douglass, LM
Sankar, R

Publication Date
2014-10-01

DOI
10.1111/epi.12567

Peer reviewed
Lennox-Gastaut syndrome (LGS) is a severe epileptic encephalopathy in which the epileptiform abnormalities may contribute to progressive dysfunction. Characterized by polymorphic seizures and neuropsychological decline, patients with LGS account for 5–10% of children with seizures. Prognosis for LGS is very poor: 5% of children die, 80–90% continue having seizures into adulthood, and nearly all have cognitive and behavioral problems. In a population-based cohort of 688 children in Atlanta, Georgia, the risk of death among children with Lennox-Gastaut syndrome was 14 times greater than that of children, adolescents, and young adults in the general population; most deaths resulted from neurologic causes, often with seizures cited as the precipitating factor. This finding suggests that optimal seizure control may contribute to reduced mortality in patients with LGS.

Accurate and early diagnosis of LGS is essential for effective management and for improving clinical outcomes. This goal, however, is often elusive for many reasons. Because LGS may arise from multiple etiologies, the clinical presentation varies, demonstrating variable seizure types and electroencephalogram (EEG) features that often change over time, thereby complicating the diagnostic process. As with many disease processes, LGS has no biologic markers. But perhaps the most confounding diagnostic factor arises from the medical community itself, which is divided about the specific limits, features, and causes of LGS. Given the polymorphic nature of LGS, it is often confused with other syndromes,
which delays diagnosis and effective management. The complex and highly variable presentation of LGS requires a systematic approach toward evaluation and diagnosis.

**Presentation and Clinical Characteristics**

Occurring with a slight male predominance, LGS most commonly first manifests in children between 3 and 5 years of age, but onset can also occur at younger and older ages—even into adulthood. LGS is sometimes preceded by West syndrome, potentially delaying diagnosis. In symptomatic cases, LGS most frequently occurs secondary to damage to the brain resulting from prenatal or perinatal insult, infection, malformations, or tumor. However, approximately one fourth to one third of LGS cases have no clear etiology, with some cases possibly involving genetic factors.

The classic diagnostic criteria for LGS consists of a triad of features: multiple seizure types, abnormal EEG, and cognitive impairment (Fig. 1). Age at onset, abnormal or normal brain imaging, and causative factors are generally not thought to be important. The multiple seizure types during sleep is the feature often used as the foundation for diagnosis, but in fact LGS is characterized by multiple concurrent seizure types: tonic, atypical absence seizures, atonic, and myoclonic jerks. Nonconvulsive status epilepticus, lasting days to weeks, occurs in half of patients. Some experts contend that atypical absences must be present for an LGS classification, but others prefer tonic seizures as the defining diagnostic feature. The first clinical sign is often the occurrence of sudden tonic or atonic falls, referred to as “drop attacks.” At least 50% of patients with LGS experience drop attacks. They typically are preceded by a single generalized myoclonic jerk followed by a tonic contraction of axial muscles or axial atony, or a combination, leading to a sudden fall and injury; patients sometimes wear a helmet with a full face mask to prevent head trauma. Other seizure types that occur in LGS include focal, generalized tonic–clonic, and unilateral clonic manifestations, often evolving from one type to another over time.

**Abnormal EEG**

Characteristically, abnormal EEGs show slow spike-wave complexes (originally known as the petit mal variant) at <3 Hz that occur during wakefulness. The complexes typically consist of a spike (duration <70 msec) or a sharp wave (70–200 msec), followed first by a positive deep “trough,” and then a negative wave (350–400 msec). Not every wave, however, is preceded by a spike. The bursts can wax and wane, with no clear onset and offset. Although slow spike waves often occur during the seizure, they are sometimes interictal and may not manifest in any clinically observable manner. This allows for diagnostic differentiation from extended 3 Hz spike-wave discharges, which typically are accompanied by notable clinical changes.

In LGS, paroxysmal fast rhythms (10–20 Hz) occur mainly during non–rapid eye movement (REM) sleep and their presence is considered by some to be essential to the diagnosis. Paroxysmal fast rhythms are more common in the setting of LGS as compared to secondary bilateral synchrony (79% vs. 15%), and therefore can also be a consideration in the differential diagnosis. EEG patterns may change over time, manifesting focal epileptiform discharges, diffuse and focal slow waves, or disappearance of these specific abnormalities.

**Cognitive impairment**

Often accompanied by behavioral problems, cognitive impairment is a function of the epileptic encephalopathy and is an essential diagnostic feature. Ten percent to 20% of children with LGS are within accepted normal ranges for cognitive function, but have slow mental processing, making it difficult for them to perform day-to-day activities. The vast majority, however, eventually have cognitive impairment, with decreasing intelligence quotient (IQ) over time. An assessment of the long-term prognosis for patients with LGS followed for a mean of 17 years showed that 69% exhibited some degree of mental retardation at the first visit, whereas 99% exhibited mental retardation at the final follow-up visit.

Four independent risk factors for severe cognitive impairment in patients with LGS have been identified: nonconvulsive status epilepticus (NCSE), a previous diagnosis of West syndrome, myoclonic jerks, and a previous diagnosis of West syndrome.
syndrome, a symptomatic etiology of epilepsy, and an early age at onset of epilepsy. NCSE appears to be the most important risk factor for severe cognitive impairment. Although one third of patients experience normal cognitive development prior to seizure onset, most show developmental impairment beforehand.29
Behavioral problems, such as hyperactivity, aggression, and autistic traits occur in half of cases. These behaviors are more marked in early onset or symptomatic LGS.7

Differential Diagnosis

LGS can be differentiated from other epilepsy syndromes based on history and EEG characteristics, but achieving an accurate diagnosis can be challenging.5 Not all patients with LGS display the characteristic triad of features, particularly at onset.4,14 Table 1 highlights typical features and characteristics of various epileptic syndromes to support attempts to achieve a differential diagnosis.5,9,15–18

Despite clear parameters and distinguishing clinical features, significant overlap exists between LGS and other early-onset epileptic encephalopathies. Drop attacks, which are seen frequently in LGS patients, occur in many other syndromes. Epilepsies that share this or other characteristics of LGS include focal epilepsies with secondary bilateral synchrony, myoclonic–astatic epilepsy (Doose syndrome), Dravet syndrome,7 West syndrome,12 and atypical benign partial epilepsy of childhood.18 There is a tendency to incorrectly diagnose LGS whenever there are multiple seizure types or drop attacks.14 One retrospective study reported misdiagnosis in at least 29 of 103 patients who were referred with a diagnosis of LGS.19 It is important to differentiate LGS from other forms of epilepsies because of differences in prognosis and approaches to treatment.4,5

The diagnosis of LGS versus other severe generalized epilepsies of childhood must be based on a detailed history, and awake and asleep EEGs with polygraphic recording, which are sometimes repeated.5 Two thirds or more of patients with LGS have abnormal magnetic resonance imaging (MRI) findings, which is used to detect subtle focal lesions.2

Steps for Evaluating LGS: A Proposed Algorithm

In June 2012, a group of LGS experts were convened to discuss approaches to the differential diagnosis of LGS and to the identification of a possible underlying etiology.

<table>
<thead>
<tr>
<th>Syndrome</th>
<th>Age of onset</th>
<th>EEG</th>
<th>Tonic seizure</th>
<th>Atonic seizure</th>
<th>Intellect impaired</th>
<th>Other seizure types</th>
</tr>
</thead>
<tbody>
<tr>
<td>LGS</td>
<td>1–8 years</td>
<td>&lt;3 Hz sp wave and</td>
<td>80–90% in sleep</td>
<td>Some</td>
<td>Yes</td>
<td>All</td>
</tr>
<tr>
<td></td>
<td></td>
<td>10 Hz in sleep</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MAE/Doose</td>
<td>1–5 years</td>
<td>4 Hz theta and G PSW</td>
<td>++</td>
<td>++</td>
<td>Rarely</td>
<td>M</td>
</tr>
<tr>
<td>Dravet/SIME</td>
<td>&lt;1 year</td>
<td>Slow with irregular spike wave</td>
<td>Rare</td>
<td>Rare</td>
<td>Yes</td>
<td>M</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>AA, GTC, Focal</td>
</tr>
<tr>
<td></td>
<td>at 2–3 years</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>West</td>
<td>Usually &lt;1 year</td>
<td>Hypsarrhythmia</td>
<td>Yes</td>
<td>Yes</td>
<td>Usually impaired</td>
<td>M</td>
</tr>
<tr>
<td>Pseudo</td>
<td>2–5 years</td>
<td>Central spikes and GSW</td>
<td>No</td>
<td>Yes</td>
<td>26–56%</td>
<td>AA, Focal</td>
</tr>
<tr>
<td>Lennox (ABPE)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

AA, atypical absence; ABPE, atypical benign partial epilepsy; EEG, electroencephalogram; GSW, generalized spike wave; GTC, generalized tonic–clonic; LGS, Lennox–Gastaut syndrome; M, myoclonus; MAE, myoclonic–astatic epilepsy; PSW, polyspike and wave; SIME, severe infantile myoclonic epilepsy.5,9,15–18

Figure 3. Fast rhythms during sleep, considered by some experts to be key to the differential diagnosis of LGS. Courtesy of Blaise F. D. Bourgeois. Epilepsia © ILAE
Although there were areas of consensus, some advocated tests not used by others. Experts called for, at a minimum, awake and asleep EEGs, as well as physical examination (in particular neurologic deficits, skin changes, fibromas, heart murmur) and ophthalmologic examination (retinal abnormalities, visual impairment) together with medical and social history and head MRIs. Some of the neurologists also advocated for utilization of video-EEGs with electromyogram (EMG) electrodes, and genetic/chromosomal microarrays, although these were not used universally.

If the underlying etiology was not identified following these investigations, some experts called for further testing, in particular DNA microarray, SLC2A1 (glucose transporter defect), CLN2 (late infantile neuronal ceroid lipofuscinosis), and TSC 1.2 (tuberous sclerosis). Some of these tests are considered when the condition deteriorates. It is observed that different centers have different approaches to doing the tests on a regular basis. Genetics and metabolism consultations were recommended by some experts, as well as ophthalmology (e.g., retinal hamartomas in tuberous sclerosis, visual loss in lipofuscinosis), and cardiology (e.g., murmurs) and ophthalmologic examination (retinal abnormalities in lipofuscinosis) and cardiology (e.g., rhabdomyomas in tuberous sclerosis).

**ADDITIONAL CONFOUNDING FACTORS**

Aside from clinical challenges to differential diagnosis, additional barriers exist. Frequently, parents are unwilling to accept the diagnosis due to the negative prognosis involved. As a group, community child neurologists tend to be less familiar with the diagnostic criteria of LGS and thus more hesitant to make the diagnosis, preferring to call it "mixed seizure disorder." Lack of access to specialists and lack of insurance coverage pose additional obstacles to diagnosis.

**CONCLUSIONS**

The diagnosis of LGS is derived from careful evaluation of both clinical and electrographic abnormalities. These include multiple seizure types (tonic seizures, atonic seizures, and atypical absence seizures); EEG with generalized slow spike-wave during the waking state and bursts of generalized paroxysmal fast activity often seen during sleep; as well as cognitive and behavioral impairment. There is significant overlap between LGS and other epilepsy syndromes, making the differential diagnosis particularly challenging. A complete evaluation of the medical history, along with an EEG in waking and sleep states, is critical for accurate diagnosis of the syndrome. A comprehensive physical examination and additional investigations may help to identify a possible underlying etiology. Although making a differential diagnosis can be challenging, it is important for determining prognosis and can impact treatment decisions. Additional approaches to the differential diagnosis proposed in this article may be considered in suspected cases of LGS.

**ACKNOWLEDGMENTS**

The meeting of the expert committee convened to discuss the differential diagnosis of LGS in June 2012 in Chicago, Illinois. This meeting was supported by a grant from Eisai Inc., which had no direct control of the group's activities. Writing support for this manuscript was provided by Arci J. Fader, PhD, of MedVal Scientific Information Services, LLC, and by Genevieve Belfiglio, RN, MA, agent of MedVal Scientific Information Services, LLC, and was funded by Eisai Inc., which did not have editorial control of the content. This manuscript is an original work and was prepared according to the International Society for Medical Publication Professionals' Good Publication Practice for Communicating Company-Sponsored Medical Research: The GPP2 Guidelines.

**CONFLICT OF INTEREST**

Dr. Bourgeois served as a consultant to Upsher-Smith Laboratories, Inc.; received research support from Lundbeck Inc.; received royalties from the publication of Pediatric Epilepsy, 3rd Edition and The Epilepsy Prescriber’s Guide to Antiepileptic Drugs; and is one of several people holding a patent on technology that allows patient-specific early seizure detection based on EEG recording in patients with epileptic seizures. He is a member of the Data and Safety Monitoring Board for a multicenter drug trial conducted by Pfizer. Dr. Douglass received unrestricted educational grants from Eisai Inc. to conduct continuing medical education programs and to submit manuscripts from the proceedings of these meetings. Dr. Douglass has also received research support from Questcor Pharmaceuticals to study quality care indicators for infantile spasms. Dr. Sankar has received a research grant from Pfizer, and is co-investigator in a grant from BlueBird Bio for a gene therapy treatment trial for adrenoleukodystrophy. He has served as a consultant for Lundbeck, Union Chimique Belge, Supernus, Upsher-Smith, and Acorda Therapeutics and has received speaker's fees from Union Chimique Belge, GlaxoSmithKline, Lundbeck, Supernus, and Cyberonics. Dr. Sankar also has received royalties for book authorship from CRC Press and Demos Publishers. The authors confirm that they have read the Journal’s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

**AUTHORSHIP STATEMENT**

Drs. Bourgeois, Douglass, and Sankar all fully qualify for authorship of the manuscript, having met author criteria recently updated and released by the International Committee of Medical Journal Editors. All of the authors were involved in drafting and critically revising the manuscript for important intellectual content, reviewed the final manuscript, and gave approval for submission. Drs. Bourgeois, Douglass, and Sankar are all accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

**NOTE**

Members of the expert committee included John M. Pellock (co-chairman), Richmond, VA; James W. Whelless, (co-chairman) Memphis, TN; Blaise F.D. Bourgeois, Boston, MA; Laurie M. Douglass, Boston, MA; Patricia A. Gibson, Winston-Salem, NC; Tracy A. Glauser, Cincinnati, OH; Eric H.W. Kossoff, Baltimore, MD; Georgia D. Montouris, Boston, MA; Jay Salpeter, Baltimore, MD; Raman Sankar, Los Angeles, CA; W. Donald Shields, Los Angeles, CA; Christina SanInnocencio, New York, NY.

**REFERENCES**

2. Panayiotopoulos C. Epileptic encephalopathies in infancy and early childhood in which the epileptiform abnormalities may contribute to